These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23721058)

  • 1. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
    Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers and hepatocyte growth factor in sustained hemodialysis hypotension.
    Lee CT; Hsu CY; Lam KK; Lin CR; Chen JB
    Artif Organs; 2005 Dec; 29(12):980-3. PubMed ID: 16305655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin, TNF-alpha and Interleukin-18 Correlate and are Together with Klotho Related to Other Growth Factors and Cytokines in Haemodialysis Patients.
    Almroth G; Lönn J; Uhlin F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2016 Jan; 83(1):58-63. PubMed ID: 26448366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac and proinflammatory markers predict prognosis in cirrhosis.
    Wiese S; Mortensen C; Gøtze JP; Christensen E; Andersen O; Bendtsen F; Møller S
    Liver Int; 2014 Jul; 34(6):e19-30. PubMed ID: 24313898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
    Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
    Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM
    Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
    Kolho KL; Valtonen E; Rintamäki H; Savilahti E
    Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-18 is involved in vascular injury in end-stage renal disease patients.
    Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
    Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
    Lindqvist M; Wallinder J; Henriksson AE
    Thromb Res; 2012 Sep; 130(3):511-3. PubMed ID: 22633212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
    Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
    Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.